公开(公告)号：US20230303538A1

公开(公告)日：2023-09-28

申请号：US17927426

申请日：2021-05-27

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： CHUNJIAN LIU ,  Wei Wang ,  Bruce A. Ellsworth ,  James Aaron Balog ,  Alicia Regueiro-Ren

IPC分类号： C07D405/14

CPC分类号： C07D405/14

摘要： The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US20230295321A1

公开(公告)日：2023-09-21

申请号：US17934012

申请日：2022-09-21

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： MAREK HONCZARENKO ,  VAISHALI SHAH ,  LIXIN LANG ,  URVI ARAS ,  DIANE SHEVELL ,  CHRISTINE KRATT ,  KAREN PRICE ,  SUZANNE SUCHARD

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

摘要： Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, Pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

公开(公告)号：US20230295122A1

公开(公告)日：2023-09-21

申请号：US18041719

申请日：2021-08-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： David S. Yoon ,  Alicia Regueiro-Ren ,  Michael Mandler ,  Shoshana L. Posy ,  Chunjian Liu

IPC分类号： C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

CPC分类号： C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

摘要： The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

公开(公告)号：US11760763B2

公开(公告)日：2023-09-19

申请号：US17477649

申请日：2021-09-17

申请人： Celgene CAR LLC

发明人： Jian Guo ,  John Malona ,  Alexander L. Ruchelman ,  Sekhar S. Surapaneni

IPC分类号： C07D495/14 ,  A61K31/551

CPC分类号： C07D495/14

摘要： The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

公开(公告)号：US20230255964A1

公开(公告)日：2023-08-17

申请号：US17639489

申请日：2020-09-18

申请人： Bristol-Myers Squibb Company

发明人： Sherif Ibrahim Farag Badawy ,  Jonathan R. Brown ,  Candice Y. Choi ,  Christoph Gesenberg ,  Vivienne Gary ,  John Wynne Jones ,  Umesh Kestur ,  Balvinder S. Vig ,  Xiaotian S. Yin ,  Christopher A. Zordan ,  Corey Bloom ,  Ian Yates

IPC分类号： A61K31/501 ,  A61K9/20

CPC分类号： A61K31/501 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054

摘要： Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyrid azine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

公开(公告)号：US20230250063A1

公开(公告)日：2023-08-10

申请号：US18004722

申请日：2021-07-08

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： James A. Johnson ,  Zulan Pi ,  Nicholas R. Wurtz ,  Joanne M. Smallheer ,  Meriah Neissel Valente ,  Ellen K. Kick ,  Charles G. Clark ,  Pravin Sudhaka Shirude ,  Balaji Kumar Seshadri ,  Amit Kumar Chattopadhyay

IPC分类号： C07D231/50 ,  C07D405/14 ,  C07D401/14 ,  C07D451/02 ,  C07D413/14 ,  C07D401/04

CPC分类号： C07D231/50 ,  C07D405/14 ,  C07D401/14 ,  C07D451/02 ,  C07D413/14 ,  C07D401/04

摘要： The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US11701373B2

公开(公告)日：2023-07-18

申请号：US17307138

申请日：2021-05-04

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Alaric J. Dyckman ,  T. G. Murali Dhar ,  Hai-Yun Xiao ,  John L. Gilmore ,  Michael G. Yang ,  Zili Xiao ,  David Marcoux

IPC分类号： A61K31/695 ,  C07F7/08 ,  A61K31/135 ,  C07D215/14 ,  C07D241/04 ,  C07C323/29 ,  C07C251/38 ,  C07C251/42 ,  C07C251/44 ,  C07D209/46 ,  C07D213/38 ,  C07C275/26 ,  C07C217/74 ,  C07C323/25 ,  C07C235/46 ,  C07F9/54 ,  C07F9/572 ,  C07F9/09 ,  C07C215/42 ,  C07C217/52 ,  C07C217/58 ,  C07C219/24 ,  C07C233/41 ,  C07C233/65 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C271/34 ,  C07C317/28 ,  C07C317/32 ,  C07C321/16 ,  C07C321/22 ,  C07C321/28 ,  C07D213/32 ,  C07D213/69 ,  C07D213/70 ,  C07D215/12 ,  C07D217/24 ,  C07D231/12 ,  C07D231/20 ,  C07D239/26 ,  C07D241/12 ,  C07D277/24 ,  C07D305/08 ,  C07D309/06 ,  C07D309/12 ,  C07D311/58 ,  C07D311/76 ,  C07D319/20 ,  C07D333/16 ,  C07F9/117 ,  C07F9/62 ,  C07F9/6503 ,  C07F9/6509 ,  C07F9/655 ,  C07F9/6553 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/166 ,  A61K31/17 ,  A61K31/222 ,  A61K31/24 ,  A61K31/27 ,  A61K31/337 ,  A61K31/351 ,  A61K31/352 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/661

CPC分类号： A61K31/695 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/166 ,  A61K31/17 ,  A61K31/222 ,  A61K31/24 ,  A61K31/27 ,  A61K31/337 ,  A61K31/351 ,  A61K31/352 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/661 ,  C07C215/42 ,  C07C217/52 ,  C07C217/58 ,  C07C217/74 ,  C07C219/24 ,  C07C233/41 ,  C07C233/65 ,  C07C235/46 ,  C07C251/38 ,  C07C251/42 ,  C07C251/44 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C271/34 ,  C07C275/26 ,  C07C317/28 ,  C07C317/32 ,  C07C321/16 ,  C07C321/22 ,  C07C321/28 ,  C07C323/25 ,  C07C323/29 ,  C07D209/46 ,  C07D213/32 ,  C07D213/38 ,  C07D213/69 ,  C07D213/70 ,  C07D215/12 ,  C07D215/14 ,  C07D217/24 ,  C07D231/12 ,  C07D231/20 ,  C07D239/26 ,  C07D241/04 ,  C07D241/12 ,  C07D277/24 ,  C07D305/08 ,  C07D309/06 ,  C07D309/12 ,  C07D311/58 ,  C07D311/76 ,  C07D319/20 ,  C07D333/16 ,  C07F7/08 ,  C07F7/081 ,  C07F9/091 ,  C07F9/117 ,  C07F9/5442 ,  C07F9/5728 ,  C07F9/62 ,  C07F9/65031 ,  C07F9/65522 ,  C07F9/650952 ,  C07F9/655345 ,  C07B2200/05 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2602/10 ,  C07C2603/74

摘要： Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):




and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US11697646B2

公开(公告)日：2023-07-11

申请号：US17224161

申请日：2021-04-07

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC分类号： C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  A61P1/16 ,  A61P19/10 ,  A61P13/12 ,  A61P11/00 ,  C07C249/06 ,  C07C403/04

CPC分类号： C07D401/04 ,  A61P35/00 ,  C07C249/06 ,  C07C403/04 ,  C07D249/06 ,  C07D403/04 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/10

摘要： The present invention provides compounds of Formula (I):




or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20230203039A1

公开(公告)日：2023-06-29

申请号：US17760309

申请日：2021-02-05

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Khehyong Ngu ,  Christopher Annunziato ,  John V. Duncia ,  Daniel Gardner

IPC分类号： C07D471/22 ,  C07D498/22 ,  C07D487/22 ,  C07D519/00 ,  A61K45/06

CPC分类号： C07D471/22 ,  C07D498/22 ,  C07D487/22 ,  C07D519/00 ,  A61K45/06

摘要： The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, (I) wherein ring A, A1, A2, A3, A4, Q, R1, R2, R3, R4, R5, and R6 along with other variables are as defined herein.

公开(公告)号：US11685787B2

公开(公告)日：2023-06-27

申请号：US16612956

申请日：2018-05-15

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Suba Krishnan ,  Penny E. Phillips ,  Zheng Yang ,  Haiqing Wang

IPC分类号： A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/75 ,  C07K2317/76

摘要： Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody.